Recently by John Pennett
Balancing Revenue Against Risk: Education and zero tolerance for deficiencies are key
John Pennett’s Life Sciences practice at EisnerAmper ranges from fledgling companies in incubators to global pharmaceuticals, but his insights here on implementing compliance controls, assessing reputational risk and vetting third-party vendors are widely applicable. His remarks have been...
Read MoreThe Long Arm Of Sarbanes-Oxley: Extending To Private And Non-Profit Organizations
Editor: Why is it beneficial for a private company or nonprofit to become Sarbanes-Oxley compliant or at the least partially compliant? Pennett: Adopting Sarbanes-Oxley principles is beneficial for both private and non-profits insofar as this ensures better controls, proper corporate governance...
Read MoreCurrent Sarbanes-Oxley's Section 404 - A Hardship For Small Companies
During my 23 years of accounting experience (more than half of which have been involved in working with small life sciences clients, primarily biotech firms) I have witnessed many changes in cost and manpower issues. Most recently, I have seen the increased burden of cost and manpower imposed by...
Read More